The CBP/p300 HAT inhibitor A-485 shows potent anticancer activity against acute myeloid leukaemia, multiple myeloma and non-Hodgkin's lymphoma cells 90. This evidence concerns the gene TMPRSS11D and acute myeloid leukemia.